# Neoadjuvant Sequential Therapy in Locally Advanced Mid/Low Rectal Cancer

> **NCT02022852** · PHASE2 · UNKNOWN · sponsor: **Harbin Medical University** · enrollment: 80 (estimated)

## Conditions studied

- Rectal Cancer

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** XELOX

## Key facts

- **NCT ID:** NCT02022852
- **Lead sponsor:** Harbin Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-07
- **Primary completion:** 2015-07
- **Final completion:** 2018-01
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2013-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02022852

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02022852, "Neoadjuvant Sequential Therapy in Locally Advanced Mid/Low Rectal Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02022852. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*